Mina Mawani, President & CEO of Crohn’s and Colitis Canada and Dr. Laura Targownik, Clinician Scientist and Gastroenterologist at Mount Sinai Hospital in Toronto and Division Director for Gastroenterology at University of Toronto discuss some of the key findings in the ‘Impact of IBD in Canada Report’, especially related to healthcare costs associated with IBD. More specifically, we discuss a key patient issue that is pertinent today and that is forced switching or non-medical switching from biologics to biosimilars.
Crohn’s and Colitis Canada urges us all to take action! See http://action.crohnsandcolitis.ca/ for more details.
Podcast: Play in new window | Download
